Eli Lilly Challenges EMA Decision on Alzheimer’s Drug ApprovalEli Lilly seeks reexamination of its Alzheimer's drug, Keysunra, after EMA denied approval due to brain swelling concerns.
Lilly’s Weight-Loss Pill Looks Strong in Trials—Ozempic’s Reign in Jeopardy?Eli Lilly's new diabetes pill matches Ozempic's effectiveness, with hopes for regulatory approval and a growing obesity treatment market.
New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side EffectsEli Lilly's Lepodisiran shows a 93.9% reduction in lipoprotein levels, a key heart disease risk factor, in mid-stage trials.
Eli Lilly Moves First in India, Beats Novo in Obesity Drug ShowdownEli Lilly launches Mounjaro in India, targeting a large market and competing with Novo Nordisk's Wegovy for obesity treatment.
Must-Reads
1
Trump Claims Epstein 'Stole' Young Women from Mar-a-Lago Spa
LATEST
2
Say Hello to Your New Beauty Buddy: AI-Powered Kiosks Hit GS25 Stores!
LATEST
3
New Task Force Takes Aim at Stock Manipulators: A Game Changer for Investors!
LATEST
4
COP30 Chaos: Will Brazil's Soaring Hotel Prices Keep Poor Nations Out of Climate Talks?
LATEST
5
Is Tesla Behind LG Energy's Massive Battery Supply Contract?
Hot Topics